66th ASH Annual Meeting: Shifting to Higher Standards in MDS: Custom and Innovative Care to Improve Outcomes for Lower- and Higher-Risk Disease

Sponsor: independent educational grants from AbbVie, Bristol Myers Squibb, and Geron.

Friday Satellite Symposia

Research, MDS, Clinical Practice (Health Services and Quality), Workforce, Education, Chronic Myeloid Malignancies, Diseases, Treatment Considerations, Adverse Events, Myeloid Malignancies, Biological Processes

San Diego Ballroom AB (Marriott Marquis San Diego Marina)

Chair:

Guillermo Garcia-Manero, MD, The University of Texas MD Anderson Cancer Center

Disclosures:

Garcia-Manero: Astex: Other: Personal fees; Aprea: Research Funding; H3 Biomedicine: Research Funding; Amphivena: Research Funding; Bristol Myers Squibb: Other: Personal fees, Research Funding; Onconova: Research Funding; Helsinn: Other: Personal fees; Forty Seven: Research Funding; Astex: Research Funding; Merck: Research Funding; Helsinn: Research Funding; Janssen: Research Funding; Curis: Research Funding; Genentech: Research Funding; Genentech: Other: Personal fees; AbbVie: Research Funding; Novartis: Research Funding.

Speakers:

Maria Diez-Campelo, MD, PhD, University Hospital of Salamanca, IBSAL and Valeria Santini, MD, AOU Careggi, University of Florence

Disclosures:

Diez-Campelo: ASTEX/OTSUKA: Membership on an entity's Board of Directors or advisory committees, Other: TRAVEL TO MEETINGS; CURIS: Membership on an entity's Board of Directors or advisory committees; SYROS: Membership on an entity's Board of Directors or advisory committees; BMS/Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Advisory board fees; Gilead: Other: Travel reimbursement; HEMAVAN: Membership on an entity's Board of Directors or advisory committees; GSK: Consultancy, Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; KEROS: Honoraria, Membership on an entity's Board of Directors or advisory committees; BLUEPRINT MEDICINES: Consultancy, Membership on an entity's Board of Directors or advisory committees; AGIOS: Consultancy, Membership on an entity's Board of Directors or advisory committees.

On Demand program will be available here December 30, 2024.

Access Program Here

This CME/MOC/AAPA activity is provided by PVI, PeerView Institute for Medical Education and developed with our educational partner, the HealthTree Foundation for MDS.

In collaboration with our partner the HealthTree Foundation for MDS, PeerView’s unique Seminars & Tumor Board live event will pair compelling case scenarios and collaborative decision-making (designed to mimic the back-and-forth of real-world tumor boards) with practice-changing evidence to provide guidance on the skills and strategic planning that inform treatment individualization across the spectrum of MDS management—while addressing real-world barriers that can prevent accurate patient assessment and hinder the delivery of modern therapeutic standards. Throughout the activity, a panel of leading MDS experts will collaboratively illustrate:

Updated methods for diagnosis, symptom identification, and prognostic assessment

The informed selection of innovative therapies as standard 1L management of MDS anemia, in the care of ESA-refractory patients, and in settings defined by specific mutations (eg, TP53 mutations) or cytogenetics

Team-based strategies for effective and continuous delivery of care, including appropriate dosing, safety management, and judicious therapeutic sequencing in both LR- and HR-MDS settings

Join our experts to elevate your MDS management and standards of care!

See more of: Friday Satellite Symposia

<< Previous Application | Next Application >>